Effects of rosiglitazone on serum retinol-binding protein 4 and hepatic fat contents in patients with type 2 diabetes mellitus
BAO Yuqian,WU Haiya,QIU Huiling,ZHU Jiehua,WANG Ren,JIA Weiping
2008-01-01
Abstract:Objective To investigate the changes of serum retinol-binding protein 4,hepatic fat content,carbohydrate and lipid metabolism in patients with type 2 diabetes mellitus before and after the treatment with rosiglitazone.Methods Seventeen subjects newly-diagnosed with type 2 diabetes mellitus,aged between 35 to 69 years,were treated with rosiglitazone(4-8 mg/d)for 24 weeks.The wight,waist and hip circumference were measured before and after the rosiglitazone treatment.Fasting plasma glucose(FPG),2 hours plasma glucose(2hPG),HbA1c,lipid,retinol-binding protein 4(RBP4)and adiponectin(APN)were determined at the same time.Hepatic fat content was measured by ultrasound histogram.B-cell function was evaluated by arginine stimulating test,insulin sensitivity was estimated by homeostasis model assessment(HOMA).The trial adopted a self-controlling methods.Results Compared with baseline levels,the levels of FPG,2hPG,HbA1c and RBP4 were significantly decreased,and APN level was increased during rosiglitazone treatment(all P<0.01).After treatment,the attenuation coefficients of liver adipose content in the longitudinal section under the xiphoid of left hepatic lobe,the section between the ribs of right hepatic lobe,oblique section under the ribs of right hepatic lobe,and its mean value decreased by 19.5%,26.7%,22.0% and 22.9%,respectively.Conclusion Rosiglitazone can decrease serum RBP4 level,reduce the hepatic fat content in patients with type 2 diabetes,and improve insulin resistance.(Shanghai Med J,2008,3:767-770)